These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20530709)

  • 1. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.
    Vallera DA; Oh S; Chen H; Shu Y; Frankel AE
    Mol Cancer Ther; 2010 Jun; 9(6):1872-83. PubMed ID: 20530709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma.
    Oh S; Stish BJ; Sachdev D; Chen H; Dudek AZ; Vallera DA
    Clin Cancer Res; 2009 Oct; 15(19):6137-47. PubMed ID: 19789305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.
    Oh S; Todhunter DA; Panoskaltsis-Mortari A; Buchsbaum DJ; Toma S; Vallera DA
    Pancreas; 2012 Jul; 41(5):789-96. PubMed ID: 22258068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.
    Oh S; Tsai AK; Ohlfest JR; Panoskaltsis-Mortari A; Vallera DA
    J Neurosurg; 2011 Jun; 114(6):1662-71. PubMed ID: 21294620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.
    Hansen JK; Weldon JE; Xiang L; Beers R; Onda M; Pastan I
    J Immunother; 2010 Apr; 33(3):297-304. PubMed ID: 20445350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
    Tsai AK; Oh S; Chen H; Shu Y; Ohlfest JR; Vallera DA
    J Neurooncol; 2011 Jun; 103(2):255-66. PubMed ID: 20830604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues.
    Schweizer A; Wöhner M; Prescher H; Brossmer R; Nitschke L
    Eur J Immunol; 2012 Oct; 42(10):2792-802. PubMed ID: 22777817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the
    Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
    Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher cytotoxicity of divalent antibody-toxins than monovalent antibody-toxins.
    Won J; Nam P; Lee Y; Choe M
    Biochem Biophys Res Commun; 2009 Apr; 382(1):15-20. PubMed ID: 19245794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
    Onda M; Beers R; Xiang L; Nagata S; Wang QC; Pastan I
    Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11311-6. PubMed ID: 18678888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.
    Schmohl JU; Todhunter D; Taras E; Bachanova V; Vallera DA
    Toxins (Basel); 2018 Jan; 10(1):. PubMed ID: 29316610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
    Weldon JE; Xiang L; Chertov O; Margulies I; Kreitman RJ; FitzGerald DJ; Pastan I
    Blood; 2009 Apr; 113(16):3792-800. PubMed ID: 18988862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
    Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
    Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
    Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
    Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies.
    Mansfield E; Pastan I; FitzGerald DJ
    Bioconjug Chem; 1996; 7(5):557-63. PubMed ID: 8889017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.
    Liu W; Onda M; Kim C; Xiang L; Weldon JE; Lee B; Pastan I
    Protein Eng Des Sel; 2012 Jan; 25(1):1-6. PubMed ID: 22101015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.
    Kawa S; Onda M; Ho M; Kreitman RJ; Bera TK; Pastan I
    MAbs; 2011; 3(5):479-86. PubMed ID: 22048691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.
    Bachanova V; Frankel AE; Cao Q; Lewis D; Grzywacz B; Verneris MR; Ustun C; Lazaryan A; McClune B; Warlick ED; Kantarjian H; Weisdorf DJ; Miller JS; Vallera DA
    Clin Cancer Res; 2015 Mar; 21(6):1267-72. PubMed ID: 25770294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model.
    Sokolova EA; Shilova ON; Kiseleva DV; Schulga AA; Balalaeva IV; Deyev SM
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.